anandamide and Lymphoma--Mantle-Cell

We have earlier reported overexpression of the central and peripheral cannabinoid receptors CB1 and CB2 in mantle cell lymphoma (MCL), a B cell non-Hodgkin lymphoma. In this study, treatment with cannabinoid receptor ligands caused a decrease in viability of MCL cells, while control cells lacking CB1 were not affected. Interestingly, equipotent doses of the CB1 antagonist SR141716A and the CB1/CB2 agonist anandamide inflicted additive negative effects on viability. Moreover, treatment with the CB1/CB2 agonist Win-55,212-2 caused a decrease in long-term growth of MCL cells in culture. Induction of apoptosis, as measured by FACS/Annexin V-FITC, contributed to the growth suppressive effect of Win-55,212-2. Our data suggest that cannabinoid receptors may be considered as potential therapeutic targets in MCL.

Topics: Animals; Arachidonic Acids; Benzoxazines; Biopsy; Breast Neoplasms; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cell Death; Cell Division; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Viral; Cells, Cultured; Dose-Response Relationship, Drug; Endocannabinoids; Female; Flow Cytometry; Humans; Leukemia, Plasma Cell; Ligands; Lymphoma, Mantle-Cell; Mice; Morpholines; Naphthalenes; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Rimonabant